A Prospective Study on Efficacy and Safety of Filgrastim (Leuco-Plus 300) for Prevention of Chemotherapy Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma

Trial Profile

A Prospective Study on Efficacy and Safety of Filgrastim (Leuco-Plus 300) for Prevention of Chemotherapy Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Chemotherapy-induced damage; Neutropenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms APXF002-01
  • Sponsors Siam Bioscience
  • Most Recent Events

    • 22 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top